New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 21, 2012
09:03 EDTOREXBlue Chip says Orexigen accelerating patient enrollment for The Light Study
Blue Chip Patient Recruitment, a division of Blue Chip Marketing Worldwide, said it has partnered with Orexigen Therapeutics to accelerate patient enrollment of The Light Study, Orexigenís cardiovascular outcomes trial evaluating Contrave, an investigational medication being evaluated for the treatment of obesity. Approximately 9,000 patients will be randomized in the study within the next few weeks, nearly 14 months ahead of original forecasts, Blue Chip said.
News For OREX From The Last 14 Days
Check below for free stories on OREX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for OREX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use